R&D channel feed – Endpoints News

R&D channel feed

Updated: Taysha teases early gene therapy data for Rett syndrome

11 months ago

After two patient deaths from presumed sepsis, FDA puts partial hold on Zentalis studies

11 months ago

AstraZeneca’s Truqap combo flops in Phase 3 triple-negative breast cancer trial

11 months ago

GSK readies Blenrep's commercial re-launch in the US, and a push in second line

11 months ago

J&J cements footprint in Italy with €580M in investments over the next 5 years

11 months ago

Updated: FDA places partial hold on BioNTech-MediLink ADC after multiple deaths

11 months ago

J&J’s Sjögren’s disease drug shows promise in Phase 2, boosts prospects of FcRn assets in the autoimmune disease

11 months ago

Marinus reports mixed Phase 3 results on IV seizure drug

11 months ago

Aerovate’s stock craters after PAH drug fails Phase 2 study

11 months ago

Updated: Takeda’s Ovid-licensed drug fails two Phase 3 epilepsy studies

11 months ago

Nurix’s protein degrader overcomes resistance to BTK mutations in small leukemia study

11 months ago

With new data, AstraZeneca makes the case for its BTK inhibitor in a first-line setting

11 months ago

Gilead cancer drug magrolimab showed worrying trends around death

11 months ago

Autoimmune CAR-T data dump: Kyverna, Cabaletta shares fall after unveiling early-stage results

11 months ago

Roche details Columvi OS data in quest for expanded lymphoma approval

11 months ago

Innovent details Phase 3 weight loss data from Lilly-partnered GLP-1 in Chinese patients

11 months ago

UroGen touts long duration of response for its bladder cancer chemotherapy gel

11 months ago

J&J returns bispecific T cell engager to Xencor, reducing scope of partnership

11 months ago

Surprise flop for Cara’s oral pruritus drug forces company to cut its last R&D program

11 months ago

Barinthus Bio to lay off 25% of its workforce and focus on just two programs

11 months ago

Pfizer’s Duchenne muscular dystrophy gene therapy fails Phase 3 trial

11 months ago

Pfizer strikes an R&D partnership with Flagship's ProFound as it looks for next-gen obesity assets

11 months ago

Ultragenyx touts Phase 2 data for Mereo-partnered rare bone disorder drug as Phase 3 gets underway

11 months ago

Avidity’s early-phase data for rare muscle disease drug spur registrational plans

11 months ago

First page Previous page 37 38 394041 42 43 Next page Last page